Fibrocell Science — Investor Presentation (May 2013)
36 slides from Fibrocell Science's investor presentation, May 7, 2013
Slide 1: Fibrocell
f) FIBROCELL & May 7, 2013 SS
Slide 2: Forward Looking Statement
2 This presentation includes statements that are "forward-looking statements." Forward-looking statements include, without limitation, our ability (i) to timely commence our clinical programs in 2013 to treat patients with restrictive burn scars and vocal cord scars, and a timely completion of these
Slide 3: Investor Highlights
Investor Highlights Autologous cell therapy company on cutting edge of developing first-in-class medical applications using fibroblasts LAVIV(r) - lead product Indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults One of only three FDA-approved cell bas
Slide 4: Status
Status Aesthetic (Nasolabial Lines and Other) FDA-approved for smile line wrinkles in June 2011 Restrictive Burn Scars Phase II study initiated Efficacy data expected mid-2014 Vocal Cord Scarring Positive pilot study published in Laryngoscope; abstract online: http://www.ncbi.nlm.nih.gov/pubmed/2128
Slide 5: Unlocking the Potential of the Autologous Fibroblast
Aesthetics Autologous Fibroblast Cell Therapy for Unmet Medical Indications (Scarring) Autologous Fibroblast Cell Therapies for Rare and Ultra Rare Diseases 5 Unlocking the Potential of the Autologous Fibroblast
Slide 6: Significant Addressable Markets
6 American Society for Aesthetic Plastic Surgery. www.ameriburn.org; Goodis. J and E.d. Schraga. Burns, thermal. eMedicine Journal Personal communication with several expert burn clinicians Cohen, (2010); Dailey et al. (2007); Roy et al. (2005); Poels et al. (2003); Koufman and Isaacson (1991); Pain
Slide 7: The Autologous Fibroblast
The Autologous Fibroblast
Slide 8: Fibroblast Cells
Most common cells of connective tissue in animals Produce collagen and other extracellular matrix proteins, which form the infrastructure of human tissue Produce an array of growth factors and other cytokines that aid in cell signaling and wound repair Fibroblast Cells 8
Slide 9: Fibroblasts: Location in Skin
Fibroblasts: Location in Skin 9
Slide 10: Dermal Fibroblasts
Dermal fibroblasts produce: Collagen type I Collagen type III Collagen type VII Elastin Hyaluronic acid (hyaluronin) Matrix metalloproteinases (MMPs) (1) Artist's interpretation Dermal Fibroblasts Matrix metalloproteinases refers to a group of proteins that play an important role in tissue remodelin
Slide 11: Aesthetics
Aesthetics
Slide 12: LAVIV
12 Positioned as premium aesthetic First in New Class - Personalized Aesthetics Replaces a person's own fibroblast cells LAVIV has received recognition in national beauty and fashion magazines Allure magazine 'Breakthrough Award' Wall Street Journal Technology Innovation Awards Edison Awards Silver
Slide 13: Restrictive Burn Scarring
Restrictive Burn Scarring 13
Slide 14: Restrictive Burn Scarring: Overview
Currently no FDA-approved drugs Azficel-T treatment: potential improvement in range of motion, reduction in pain and aesthetic improvement Potential indication for unmet medical need: 45,000 yearly hospitalizations for severe burns (1) (excluding military and existing victims) Promising results in o
Slide 15: Burn Patient Case Studies
Burn Patient Case Studies * *Note: Photos from LAVIV prescribers. Not from clinical studies. These are not restrictive burn scar patients. Case 1 Case 2 15
Slide 16: Functional Benefit Demonstrated in Burn Patients
16 Burn Scars Before 5 Weeks Post Injury 7 Months Post Injury 18 Months Post Injury Area Treated with Azficel-T Note: Photos from LAVIV prescribers. Not from clinical studies. Functional Benefit Demonstrated in Burn Patients
Slide 17: Restrictive Burn Scarring: Status
Phase II Trial: Single site, double-blind, randomized, placebo- controlled, 21 subjects Subjects: Unilateral restrictive burn scars of a jointed area 20-50 percent restriction in normal range of motion; no improvement after physical therapy Measurement Scales: Range of Motion Measurement Brief Pain
Slide 18: Vocal Cord Scarring
Vocal Cord Scarring
Slide 19: Vocal Cord Scarring: Overview
No currently approved drugs Most commonly encountered finding is loss of voice Results from surgery, radiation therapy, vocal cord trauma and idiopathic causes Positive pilot study results published in peer-reviewed journal The Laryngoscope, 2011. (1) Azficel-T well-tolerated when injected into voca
Slide 20: Vocal Cord Scarring: Status
Phase II protocol submitted to FDA Estimated initiation of trial 2H 2013 Efficacy data expected in 2H 2014 Proposed Endpoints: Impression of improvement in voice quality (VAS) Change from baseline in the noise-to-harmonic ratio (dB) Absolute and percentage change from baseline in the Voice Handicap
Slide 21: Acne Scarring
Acne Scarring
Slide 22: Acne Scarring: Overview
22 No currently approved drugs Permanent discoloration and/or indentation of the skin as a result of moderate to severe acne Opportunity to capture large market share No current medical treatment Completed one Phase II study: Results published in peer-reviewed journal Dermatologic Surgery, available
Slide 23: Acne Scarring: Phase II Study Results
23 Efficacy: - Fibroblast treatment demonstrated statistically significant number of responders in subject and evaluator assessments at four months - 98% of patients who completed the study indicated interest in receiving additional treatment Safety: - Most common adverse events: erythema (11.1%), s
Slide 24: Acne Scarring: Follow-Up Photos from Study
24 Acne Scarring: Follow-Up Photos from Study 25 Month Photos Anecdotally Demonstrate Potential Long-Lasting Effect Time Photos provided by Gilly S. Munavalli, MD, MHS, FACMS, Dermatology, Laser & Vein Specialists of the Carolinas, Charlotte, NC
Slide 25: Intrexon Collaboration: Genetically Modified Fibroblasts for Rare and Ultra Rare Diseases
Intrexon Collaboration: Genetically Modified Fibroblasts for Rare and Ultra Rare Diseases
Slide 26: Intrexon Collaboration
Proposed new therapeutic product: Genetically modified (GM) fibroblast Up-regulated to produce Collagen VII Employ Intrexon's synthetic biology platforms for optimal gene expression from GM fibroblasts Pre-clinical activity underway in GM fibroblasts for rare and ultra rare diseases i.e. recessive d
Slide 27: RDEB: Overview
Initial target: recessive dystrophic epidermolysis bullosa (RDEB) Epidermolysis bullosa: genetic conditions that cause blistering and fragile skin Mutations in the COL7A1 gene cause disease This gene helps create type VII collagen Type VII collagen key in strengthening and stabilizing the skin It is
Slide 28: UCLA Collaboration: Stem Cell Program
UCLA Collaboration: Stem Cell Program
Slide 29: Stem Cell Collaboration
Identified a rare mesenchymal stem cell (MSC) population from adult human skin The data was published in the article, "Vega-Crespo et al 2013, BioResearch Open Access, 1:25" (http://online.liebertpub.com/doi/pdf/10.1089/biores.2012.0204) Goal to purify MSCs using biomarkers to identify a number of p
Slide 30: The Only Créme of Its Kind
= The Only Créme of Its Kind B
Slide 31: Autologous Creme
Personalized autologous cream Conditioned complete growth media from the azficel-T production process is collected, concentrated and used to formulate a personalized topical cosmetic 19 subject cosmetic clinical study to be completed in May 2013 Autologous Creme(tm) 31
Slide 32: Financials
Financials
Slide 33: Financial Information
Strong cash position; US $31.3 million on hand at end of December 2012 Large private capital raise completed in October 2012, investor syndicate led by Third Security, an investment firm led by RJ Kirk No debt on the balance sheet Company's capital structure greatly simplified All outstanding prefer
Slide 34: Capitalization Table
Common shares (post reverse split) 26.2M Warrants 6.3M Options .6M Fully diluted shares outstanding 33.1M Fibrocell has been cleared to submit NYSE MKT listing application Capitalization Table 34
Slide 35: Summary
Summary
Slide 36: Investor Highlights
Autologous cell therapy company on cutting edge of developing first in class medical applications Strategic focus on a robust pipeline for LAVIV medical applications: Restrictive burn scarring, vocal cord scarring and acne scarring LAVIV(r) - lead product Indicated for improvement of the appearance